Future growth expectations in earnings/operating earnings/profits/EPS?

Jubilant Ingrevia targets 3x revenue and 4x EBITDA growth by FY'29 from FY'24 base (Rs. 4,200 crore revenue in FY'24). Specialty Chemicals and Nutrition segments are expected to constitute over 75% of revenue, up from 60% currently. EBITDA margin thresholds for new contracts are set at a minimum of 20%. Incremental CAPEX of Rs. 600-800 crore expected annually for next three years to drive growth, primarily funded through internal accruals. CDMO business, including two major contracts (one $300 million, five-year duration), is a key growth driver. Continuous volume growth: Specialty Chemical vo

Current/ Expected Orderbook/ Pending Orders?

Jubilant Ingrevia has created a strong pipeline with over 100 opportunities from 120+ customer meetings. They have secured two key CDMO contracts, including a $300+ million contract over five years. The $300 million contract involves preparing their Agrochemical plant with expected production starting late calendar year 2025. Another smaller order involves a new AI (Active Ingredient) not yet commercialized, expected to start supplying early next financial year with volumes in hundreds of tons. The order book reflects both existing and prospective contracts in Pharma, Agrochemicals, Specialty

Any current/future new fundraising through debt or equity?

Jubilant Ingrevia plans incremental CAPEX of Rs. 600 to 800 crore per annum over the next three years, mainly focused on Specialty and Nutrition segments. The company intends to fund most of this CAPEX through internal accruals and EBITDA generated from existing operations. Current debt levels stand around Rs. 650-700 crore, with no plans to exceed Rs. 900-1,000 crore. Debt coverage ratio is internally targeted to remain under 1.4x. If needed, marginal increase in debt may be considered but no significant new debt or equity fundraising is planned at this stage.

Any current/future capex/capital investment/strategic investment?

Wave-I CAPEX of Rs. 2,000 crore mostly completed with investments in Specialty and Nutrition segments. Upcoming Wave-II CAPEX planned at Rs. 2,000 to 2,500 crore over the next 3 years (~Rs. 700-800 crore annually). 100% of Wave-II investment to focus on Specialty and Nutrition portfolios. CAPEX geared towards CDMO opportunities in agro, pharma, semiconductors; multipurpose plants for pyridine and diketene derivatives. Additional investments in expansion and modification of agro intermediate and active plants (~Rs. 300 crore) for $300 million CDMO contract. Strategy-led incremental CAPEX expect

Future growth expectations in sales/revenue/volumes?

Jubilant Ingrevia targets a 3x revenue increase and 4x EBITDA growth by FY'29 from the FY'24 base (Rs. 4,200 crore revenue). Specialty Chemicals and Nutrition segments are expected to form over 75% of revenue with continued volume growth. Specialty Chemical revenues grew 13% YoY with volume growth around 25%. Nutrition business revenue increased 12% YoY driven by higher sales volumes (animal and human-grade Niacinamide) and rising prices. Agrochemical demand is recovering with volumes increasing after destocking; pricing shows pockets of improvement. The company anticipates incremental CAPEX o

Jubilant Ingrevia LtdQ2 FY25Chemicals & Petrochemicals

Jubilant Ingrevia Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹638P/E: 32.9Market Cap: ₹10.5K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Jubilant Ingrevia targets a 3x revenue increase and 4x EBITDA growth by FY'29 from the FY'24 base (Rs. 4,200 crore revenue).
Specialty Chemicals and Nutrition segments are expected to form over 75% of revenue with continued volume growth.
Specialty Chemical revenues grew 13% YoY with volume growth around 25%.
Nutrition business revenue increased 12% YoY driven by higher sales volumes (animal and human-grade Niacinamide) and rising prices.
Agrochemical demand is recovering with volumes increasing after destocking; pricing shows pockets of improvement.
The company anticipates incremental CAPEX of Rs. 600-800 crore annually for the next 3 years to support growth, mostly funded via internal accruals.
CDMO contracts (including a $300 million, 5-year agrochemical contract) signal significant volume ramp-up from FY'26 onwards.
Continued focus on high-margin Specialty and Nutrition products implies improving revenue mix and margin expansion.

Margin guidance

Category 3

Jubilant Ingrevia targets 3x revenue and 4x EBITDA growth by FY'29 from FY'24 base (Rs. 4,200 crore revenue in FY'24).
Specialty Chemicals and Nutrition segments are expected to constitute over 75% of revenue, up from 60% currently.
EBITDA margin thresholds for new contracts are set at a minimum of 20%.
Incremental CAPEX of Rs. 600-800 crore expected annually for next three years to drive growth, primarily funded through internal accruals.
CDMO business, including two major contracts (one $300 million, five-year duration), is a key growth driver.
Continuous volume growth: Specialty Chemical volumes have grown ~25% YoY despite price pressures.
Nutrition segment (Niacinamide) shows steady volume increases and price improvement.
Cost-saving initiatives yielded Rs. 120 crore annual savings.
Net debt managed prudently around Rs. 650-700 crore, with a cap not to exceed Rs. 900-1,000 crore ensuring healthy coverage ratios.

See what Jubilant Ingrevia Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

Jubilant Ingrevia plans incremental CAPEX of Rs. 600 to 800 crore per annum over the next three years, mainly focused on Specialty and Nutrition segments.
The company intends to fund most of this CAPEX through internal accruals and EBITDA generated from existing operations.
Current debt levels stand around Rs. 650-700 crore, with no plans to exceed Rs. 900-1,000 crore.
Debt coverage ratio is internally targeted to remain under 1.4x.
If needed, marginal increase in debt may be considered but no significant new debt or equity fundraising is planned at this stage.

Order book

Yes

Jubilant Ingrevia has created a strong pipeline with over 100 opportunities from 120+ customer meetings.
They have secured two key CDMO contracts, including a $300+ million contract over five years.
The $300 million contract involves preparing their Agrochemical plant with expected production starting late calendar year 2025.
Another smaller order involves a new AI (Active Ingredient) not yet commercialized, expected to start supplying early next financial year with volumes in hundreds of tons.
The order book reflects both existing and prospective contracts in Pharma, Agrochemicals, Specialty Chemicals, and Nutrition segments.
The pipeline is expected to grow as the "China plus one" strategy and Bio Security Act drive increased outsourcing to India.
Jubilant expects their CDMO business contracts to be just the tip of the iceberg, anticipating conversion of multiple pipeline opportunities in coming years.

See what Jubilant Ingrevia Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Wave-I CAPEX of Rs. 2,000 crore mostly completed with investments in Specialty and Nutrition segments.
Upcoming Wave-II CAPEX planned at Rs. 2,000 to 2,500 crore over the next 3 years (~Rs. 700-800 crore annually).
100% of Wave-II investment to focus on Specialty and Nutrition portfolios.
CAPEX geared towards CDMO opportunities in agro, pharma, semiconductors; multipurpose plants for pyridine and diketene derivatives.
Additional investments in expansion and modification of agro intermediate and active plants (~Rs. 300 crore) for $300 million CDMO contract.
Strategy-led incremental CAPEX expected to be largely funded by internal accruals; aim to keep debt below Rs. 900-1,000 crore with coverage ratio under 1.4x.
New projects, including food and cosmetic grade Niacinamide plant, slated for commissioning in Q3 FY'25; more multipurpose plants planned.
Continuous focus on agile, customized facilities to meet customer demand quickly.

Track Jubilant Ingrevia Ltd — get its next earnings analysis in your feed

How does Jubilant Ingrevia Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisJubilant Ingrevia Ltd

Rev 2Mar 3

See where Jubilant Ingrevia Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Jubilant Ingrevia Ltd rank in Chemicals & Petrochemicals?

Compare Jubilant Ingrevia Ltd against every Chemicals & Petrochemicals company (Q2 FY25) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Jubilant Ingrevia Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →